An update on the roles of the complement system in autoimmune diseases and the therapeutic possibilities of anti-complement agents

Current Drug Therapy

Volumn 6, Issue 1, 2011, Pages 35-50

  Mizuno, Masashi ^a   Morgan, B Paul ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Anaphylatoxin; Autoimmune diseases; Complement; Complement 3a receptor; Membrane complement regulator; Systemic lupus erythematosus; Therapeutic strategy

Indexed keywords

ABATACEPT; AZATHIOPRINE; BELIMUMAB; COBROTOXIN; COMPLEMENT INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECULIZUMAB; EPRATUZUMAB; FICOLIN; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; MANNOSE BINDING LECTIN; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PEXELIZUMAB; RITUXIMAB; TACROLIMUS; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ADAPTIVE IMMUNITY; AEROCOCCUS VIRIDANS; ALOPECIA AREATA; ANAPHYLACTOID PURPURA; ANGIONEUROTIC EDEMA; ANKYLOSING SPONDYLITIS; APLASTIC ANEMIA; ARTICLE; ATOPIC DERMATITIS; ATROPHIC GASTRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE PANCREATITIS; B LYMPHOCYTE; BULLOUS PEMPHIGOID; CELLULAR IMMUNITY; CHURG STRAUSS SYNDROME; COLLAGEN DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CROHN DISEASE; DERMATOMYOSITIS; DIABETES MELLITUS; DRUG MEGADOSE; EOSINOPHILIC FASCIITIS; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; GRAVES DISEASE; GUILLAIN BARRE SYNDROME; HASHIMOTO DISEASE; HEPATITIS; HUMAN; HYPERTENSION; HYPOCOMPLEMENTEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL PNEUMONIA; LEUKAPHERESIS; LISTERIOSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MENINGOENCEPHALITIS; MIKULICZ DISEASE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NONHUMAN; OPPORTUNISTIC INFECTION; OPSONIZATION; OSTEOPOROSIS; PEMPHIGUS FOLIACEUS; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; POLYMYOSITIS; POSTPARTUM THYROIDITIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REITER SYNDROME; RETINA VASCULITIS; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SKIN BIOPSY; STREPTOCOCCUS PNEUMONIA; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TICK; ULCERATIVE COLITIS; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 78650965182     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488511794079031     Document Type: Article

References (291)

1. Mizuno M, Morgan BP. The possibilities and pitfalls for anti-complement therapies in inflammatory diseases. Curr Drug Targets Inflamm Allergy 2004; 3: 85-94.
2. Morgan BP, Harris CL. Complement regulatory proteins. San Diego, USA: Academic press 1999.
3. Baatrup G, Jonsson H, Sjoholm A, Sturfelt G, Svehag SE. Complement fixation by solid phase imune complexes, Reduced capacity in SLE sera. J Clin Lab Immunol 1988; 26: 73-9.
4. Molnár E, Erdei A, Prechl J. Novel roles for murine complement receptors type 1 and 2 I. Regulation of B cell survival and proliferation by CR1/2. Immunol Lett 2008; 116: 156-62.
5. Shimizu I, Kawahara T, Haspot F, Bardwell PD, Carroll MC, Sykes M. B-cell extrinsic CR1/CR2 promotes natural antibody production and tolerance induction of anti-alphaGAL-producing B1 cells. Blood 2007; 109: 1773-81.
6. Isaák A, Prechl J, Gergely J, Erdei A. The role of CR2 in autoimmunity. Autoimmunity 2006; 39: 357-66.
7. Marie JC, Astier AL, Rivailler P, Rabourdin-Combe C, Wild TF, Horvat B. Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation. Nat Immunol 2002; 3: 659-66.
8. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003; 421: 388-92.
9. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-12.
10. Suzuki K, Kameda H, Amano K, et al. Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis. Rheumatol Int 2009; 29: 431-6.
11. Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 2005; 66: 395-402.
12. Saniabadi AR, Hanai H, Takeuchi K, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003; 7: 48-59.
13. Fan PT, Leong KH. The use of biological agents in the treatment of rheumatoid arthritis. Ann Acad Med Singapore 2007; 36: 128-34.
14. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86: 242-51.
15. Davidson NJ. The therapeutic potential of anti-cytokine antibodies in the treatment of chronic inflammatory disease. Expert Opin Invest Drugs 1998; 7: 1115-20.
16. Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 2003; 3: 323-8.
17. Campbell IK, Roberts LJ, Wicks IP. Molecular targets in immunemediated diseases: the case of tumor necrosis factor and rheumatoid arthritis. Immunol Cell Biol 2003; 81: 354-66.
18. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001; 15: 463-73.
19. Mihara M, Nishimoto N, Ohsugi Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 2005; 5: 683-90.
20. Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006; 66: 1933-48.
21. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002; 74: 1207-10.
22. Tydén G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO-incompatible kidney transplantation and rituximab. Transplant Proc 2005; 37: 3286-7.
23. Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J Aust 2005; 183: 205-8.
24. Puppo F, Murdaca G, Ghio M, Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 2005; 4: 537-41.
25. Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007; 17: 191-7.
26. Golbin JM, Specks U. Targeting B lymphocytes as therapy for ANCA-associated vasculitis. Rheum Dis Clin North Am 2007; 33: 741-54.
27. Antoniu SA. Treatment options for refractory Wegener's granulomatosis: a role for rituximab? Curr Opin Investig Drugs 2007; 8: 927-32.
28. Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behçet's disease with rituximab. Mod Rheumatol 2008; 18: 306-8.
29. Arena G, Taylor R, Cascavilla N, Lindorfer M. Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia? Endocr Metab Immune Disord Drug Targets 2008; 8: 62-8.
30. Buttmann M, Rieckmann P. Treating multiple sclerosis with monoclonal antibodies. Expert Rev Neurother 2008; 8: 433-55.
31. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8: R74.
32. Conus S, Straumann A, Simon HU. Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis. J Allergy Clin Immunol 2009; 123: 269.
33. Tincani A, Andreoli L, Bazzani C, Bosiso D, Sozzani S. Inflammatory molecules: a target for treatment of systemic autoimmune diseases. Autoimmun Rev 2007; 7: 1-7.
34. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39: 327-46.
35. Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P. Listeria meningitis associated with infliximab (anti-TNF). Ann Pharmacother 2004; 38: 58-61.
36. Wagner SA, Mehta AC, Laber DA. Ituximab-induced interstitial lung disease. Am J Hematol 2007; 82: 916-9.
37. Ennishi D, Terui Y, Yokoyama M, et al. Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 2008; 87: 393-7.
38. Soubrier M, Jeannin G, Kemeny JL, et al. Organizing pneumonia after rituximab therapy: Two cases. Joint Bone Spine 2008; 75: 362-5.
39. Lim SW, Gillis D, Smith W, Hissaria P, Greville H, Peh CA. Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports. Intern Med J 2006; 36: 260-2.
40. McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 2008; 47: 552-3.
41. Farah R, Lisitsin S, Shay M. Bacterial meningitis associated with infliximab. Pharm World Sci 2006; 28: 123-5.
42. Quartier P, Tournilhac O, Archimbaud C, et al. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis 2003; 36: e47-e9.
43. Stove S, Welte T, Wagner TOF, et al. Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin Diagn Lab Immunol 1996; 3: 175-83.
44. Grim SA, Pham T, Thielke J, et al. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant 2007; 21: 628-32.
45. Rau R. Have traditional DMARDs had their day? Effectiveness of parenteral gold compared to biologic agents. Clin Rheumatol 2005; 24: 189-202.
46. Lutz HU, Jelezarova E. Complement amplification revisited. Mol Immunol 2006; 43: 2-12.
47. Fujita T, Matsushita M, Endo Y. The lectin-complement pathway-its role in innate immunity and evolution. Immunol Rev 2004; 198: 185-202.
48. Thiel S. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol Immunol 2007; 44: 3875-88.
49. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12: 682-7.
50. Kawamoto S, Yalcindag A, Laouini D, et al. The anaphylatoxin C3a downregulates the Th2 response to epicutaneously introduced antigen. J Clin Invest 2004; 114: 399-407.
51. Melendi GA, Hoffman SJ, Karron RA, et al. C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression. J Virol 2007; 81: 991-9.
52. Tsujimura M, Miyazaki T, Kojima E, et al. Serum concentration of Hakata antigen, a member of the ficolins, is linked with inhibition of Aerococcus viridans growth. Clin Chim Acta 2002; 325: 139-46.
53. Lynch NJ, Roscher S, Hartung T, et al. L-ficolin specifically binds to lipoteichoic acid, a cell wall constituent of Gram-positive bacteria, and activates the lectin pathway of complement. J Immunol 2004; 172: 1198-202.
54. Krarup A, Sørensen UB, Matsushita M, Jensenius JC, Thiel S. Effect of capsulation of opportunistic pathogenic bacteria on binding of the pattern recognition molecules mannan-binding lectin, Lficolin, and H-ficolin. Infect Immun 2005; 73: 1052-60.
55. Brouwer N, Dolman KM, van Houdt M, Sta M, Roos D, Kuijpers TW. Mannose-Binding Lectin (MBL) facilitates Opsonophagocytosis of Yeasts but not of Bacteria despite MBL Binding. J Immunol 2008; 180: 4124-32.
56. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
57. Campbell W, Okada N, Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 2001; 180: 162-7.
58. Seya T, Turner JR, Atkinson JP. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med 1986; 163: 837-55.
59. Medof ME, Kinoshita T, Nussenzweig VJ. Inhibition of complement activation on the surface of cells after incorporation of decayaccelerating factor (DAF) into their membranes. J Exp Med 1984; 160: 1558-78.
60. Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990; 71: 1-9.
61. Dobson NJ, Lambris JD, Ross GD. Characteristics of isolated erythrocyte complement receptor type one (CR1, C4b-C3b receptor) and CR1-specific antibodies. J Immunol 1981; 126: 693-8.
62. Iida K, Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J Exp Med 1981; 153: 1138-50.
63. Iida K, Nussenzweig, V. Functional properties of membrane-associated complement receptor CR1. J Immunol 1983; 130: 1876-80.
64. Molina H, Wong W, Kinoshita T, Brenner C, Foley S, Holers VM. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med 1992; 175: 121-9.
65. Takizawa H, Okada N, Okada H. Complement inhibitor of rat cell membrane resembling mouse Crry/p65. J Immunol 1994; 152: 3032-8.
66. Funabashi K, Okada N, Matsuo S, Yamamoto T, Morgan BP, Okada H. Tissue distribution of complement regulatory membrane proteins in rats. Immunology 1994;81: 444-51.
67. Hosokawa M, Nonaka M, Okada N, Nonaka M, Okada H. Molecular cloning of guinea pig membrane cofactor protein: preferential expression in testis. J Immunol 1996; 157: 4946-52.
68. Tsujimura A, Shida K, Kitamura M, et al. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): Preferential expression in testicular germ cells. Biochem J 1998; 330: 163-8.
69. Mizuno M, Harris C, Johnson P, Morgan B. Rat membrane cofactor protein (MCP; CD46) is expressed only in the acrosome of developing and mature spermatozoa and mediates binding to immobilised activated C3. Biol Reprod 2004; 71: 1374-83.
70. Mizuno M, Nishikawa K, Okada N, Matsuo S, Ito K, Okada H. Inhibition of a membrane complement regulatory protein by a monoclonal antibody induces acute lethal shock in rats primed with lipopolysaccharide. J Immunol 1999; 162: 5477-82.
71. Mizuno M, Nishikawa K, Goodfellow RM, Piddlesden SJ, Morgan BP, Matsuo S. The effects of functional suppression of a membrane-bound complement regulatory protein, CD59, in the synovial tissue in rats. Arthritis Rheum 1997; 40: 527-33.
72. Nishikawa K, Matsuo S, Okada N, Morgan BP, Okada H. Local inflammation caused by a monoclonal antibody that blocks the function of the rat membrane inhibitor of C3 convertase. J Immunol 1996; 156: 1182-8.
73. Nomura A, Nishikawa K, Yuzawa Y, et al. Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement. J Clin Invest 1995; 96: 2348-56.
74. Bardenstein SD, Cheyer JC, Lee C, et al. Blockage of complement regulators in the conjunctiva and within the eye leads to massive inflammation and iritis. Immunology 2001; 104: 423-30.
75. Boccuni P, Del Vecchio L, Di Noto R, Rotoli B. Glycosyl phosphatidylinositol (GPI)-anchored molecules and the pathogenesis of paroxysmal nocturnal hemoglobinuria. Crit Rev Oncol Hematol 2000; 33: 25-43.
76. Seya T. CD46, a complement regulatory protein/measles virus receptor, and its relation to hematological disorders. Int J Hematol 1996; 64: 101-9.
77. Gaggar A, Shayakhmetov DM, Liszewski MK, Atkinson JP, Lieber A. Localization of regions in CD46 that interact with adenovirus. J Virol 2005; 79: 7503-13.
78. Marttila M, Persson D, Gustafsson D, et al. CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J Virol 2005; 79: 14429-36.
79. Pettigrew DM, Williams DT, Kerrigan D, Evans DJ, Lea SM, Bhella D. Structural and functional insights into the interaction of echoviruses and decay-accelerating factor. J Biol Chem 2006; 281: 5169-77.
80. Hafenstein S, Bowman VD, Chipman PR, et al. Interaction of decay-accelerating factor with coxsackievirus B3. J Virol 2007; 81: 12927-35.
81. Krautkrämer E, Zeier M. Hantavirus causing hemorrhagic fever with renal syndrome enters from the apical surface and requires decay-accelerating factor (DAF/CD55). J Virol 2008; 82: 4257-64.
82. Longhi MP, Williams A, Wise M, Morgan BP, Gallimore A. CD59a deficiency exacerbates influenza-induced lung inflammation through complement-dependent and -independent mechanisms. Eur J Immunol 2007; 37: 1266-74.
83. Harris CL, Mizuno M, Morgan BP. Complement and complement regulators in the male reproductive system. Mol Immunol 2006; 43: 57-67.
84. Elward K, Griffiths M, Mizuno M, et al. CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J Biol Chem 2005; 280: 36342-54.
85. Chao TH, Ember JA, Wang M, Bayon Y, Hugli TE, Ye RD. Role of the second extracellular loop of human C3a receptor in agonist binding and receptor function. J Biol Chem 1999; 274: 9721-8.
86. Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991; 349: 614-7.
87. Gasque P, Singhrao SK, Neal JW, et al. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol 1999; 160: 3543-54.
88. Braun MC, Reins RY, Li TB, et al. Renal expression of the C3a receptor and functional responses of primary human proximal tubular epithelial cells. J Immunol 2004; 173: 4190-6.
89. Mizuno M, Blanchin S, Gasque P, Nishikawa K, Matsuo S. High levels of complement C3a receptor in the glomeruli in lupus nephritis. Am J Kidney Dis 2007; 49: 598-606.
90. Kiafard Z, Tschernig T, Schweyer S, Bley A, Neumann D, Zwirner J. Use of monoclonal antibodies to assess expression of anaphylatoxin receptors in tubular epithelial cells of human, murine and rat kidneys. Immunobiology 2007; 212: 129-39.
91. Vogt SD, Barnum SR, Curcio CA, Read RW. Distribution of complement anaphylatoxin receptors and membrane-bound regulators in normal human retina. Exp Eye Res 2006;83: 834-40.
92. Zwirner J, Götze O, Begemann G, Kapp A, Kirchhoff K, Werfel T. Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology 1999; 97: 166-72.
93. Werfel T, Kirchhoff K, Wittmann M, et al. Activated human T lymphocytes express a functional C3a receptor. J Immunol 2000; 165: 6599-605.
94. Zwirner J, Fayyazi A, Götze O. Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol 1999; 36: 877-84.
95. Akatsu H, Abe M, Miwa T, et al. Distribution of rat C5a anaphylatoxin receptor. Microbiol Immunol 2002; 46: 863-74.
96. Abe K, Miyazaki M, Koji T, et al. Enhanced expression of complement C5a receptor mRNA in human diseased kidney assessed by in situ hybridization. Kidney Int 2001; 60: 137-46.
97. Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R. C5a receptor mediated neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009; 20: 289-98.
98. Bénard M, Gonzalez BJ, Schouft MT, et al. Characterization of C3a and C5a receptors in rat cerebellar granule neurons during maturation. Neuroprotective effect of C5a against apoptotic cell death. J Biol Chem 2004; 279: 43487-96.
99. Mollnes TE, Haga HJ, Brun JG, et al. Complement activation in patients with systemic lupus erythematosus without nephritis. Rheumatology (Oxford) 1999; 38: 933-40.
100. Chiu YY, Nisihara RM, Würzner R, Kirschfink M, de Messias-Reason IJ. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients. J Investig Allergol Clin Immunol 1998; 8: 239-44.
101. Hudson M, Walker JG, Fritzler M, Taillefer S, Baron M. Hypo-complementemia in systemic sclerosis-clinical and serological correlations. J Rheumatol 2007; 34: 2218-23.
102. Ramos-Casals M, Brito-Zerón P, Yagüe J, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2005; 44: 89-94.
103. Lindgren S, Hansen B, Sjöholm AG, Manthorpe R. Complement activation in patients with primary Sjögren's syndrome: an indicator of systemic disease. Autoimmunity 1993; 16: 297-300.
104. Hamza M, Ayed K, el Euch M, Moalla M, Ben Ayed H. Synovial fluid complement levels in Behçet's disease. Ann Rheum Dis 1984; 43: 767.
105. Sjöholm AG, Berglund K, Johnson U, Laurell AB, Sturfelt G. C1 activation, with C1q in excess of functional C1 in synovial fluid from patients with rheumatoid arthritis. Int Arch Allergy Appl Immunol 1986; 79: 113-9.
106. Hasselbacher P. Immunoelectrophoretic assay for synovial fluid C3 with correction for synovial fluid globulin. Arthritis Rheum 1979; 22: 243-50.
107. Muraki T, Hamano H, Ochi Y, et al. Autoimmune pancreatitis and complement activation system. Pancreas 2006; 32: 16-21.
108. Shimoyama K, Ogawa N, Sawaki T, et al. A case of Mikulicz's disease complicated with interstitial nephritis successfully treated by high-dose corticosteroid. Mod Rheumatol 2006; 16: 176-82.
109. Bene L FG, Fekete B, Kovács A, et al. High normal serum levels of C3 and C1 inhibitor, two acute-phase proteins belonging to the complement system, occur more frequently in patients with Crohn's disease than ulcerative colitis. Dig Dis Sci 2003; 48: 1186-92.
110. Schlesinger M, Benbassat C, Shoenfeld Y. Complement profile in primary biliary cirrhosis. Immunol Res 1992; 11: 98-103.
111. Benbassat C, Schlesinger M, Shoenfeld Y. The complement system and primary biliary cirrhosis. J Clin Lab Immunol 1992; 38: 51-61.
112. Jans H, Heltberg A, Zeeberg I, Kristensen JH, Fog T, Raun NE. Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis. Acta Neurol Scand 1984; 69: 34-8.
113. Igarashi R, Takeuchi S, Sato Y. Immunofluorescent studies of complement C3 in the hair follicles of normal scalp and of scalp affected by alopecia areata. Acta Derm Venereol 1980; 60: 33-7.
114. Bystryn JC, Orentreich N, Stengel F. Direct immunofluorescence studies in alopecia areata and male pattern alopecia. J Invest Dermatol 1979; 75: 317-20.
115. Kapp A, Wokalek H, Schöpf E. Involvement of complement in psoriasis and atopic dermatitis-measurement of C3a and C5a, C3, C4 and C1 inactivator. Arch Dermatol Res 1985; 277: 359-61.
116. Hartung HP, Schwenke C, Bitter-Suermann D, Toyka KV. Guillain-Barré syndrome: activated complement components C3a and C5a in CSF. Neurology 1987; 37: 1006-9.
117. Tanaka T, Abe M, Mitsuyama T, Fukuoka Y, Sakurada T, Hara N. Hyperresponsiveness of granulocytes to anaphylatoxins, C5a and C3a, in Churg-Strauss syndrome. Intern Med 1995; 34: 1005-8.
118. Inanc N, Mumcu G, Birtas E, et al. Serum mannose-binding lectin levels are decreased in behcet's disease and associated with disease severity. J Rheumatol 2005; 32: 287-91.
119. Riis AL, Hansen TK, Thiel S, et al. Thyroid hormone increases mannan-binding lectin levels. Eur J Endocrinol 2005; 153: 643-9.
120. Rumfeld WR, Morgan BP, Campbell AK. The ninth complement component in rheumatoid arthritis, Behçet's disease and other rheumatic diseases. Br J Rheumatol 1986; 25: 266-70.
121. Sellebjerg F, Jaliashvili I, Christiansen M, Garred P. Intrathecal activation of the complement system and disability in multiple sclerosis. J Neurol Sci 1998; 157: 168-74.
122. Mascaró JMJ, Hausmann G, Herrero C, et al. Membrane attack complex deposits in cutaneous lesions of dermatomyositis. Arch Dermatol 1995; 131: 1386-92.
123. Sprott H, Müller-Ladner U, Distler O, et al. Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). J Rheumatol 2000; 27: 402-4.
124. Lamb PM, Patton T, Deng JS. The predominance of IgG4 in prodromal bullous pemphigoid. Int J Dermatol 2008; 47: 150-3.
125. Antonelli A, Palla R, Casarosa L, Fallahi P, Baschieri L. IgG, IgA and C3 deposits in the extra-thyroidal manifestations of autoimmune Graves' disease: their in vitro solubilization by intravenous immunoglobulin. Clin Exp Rheumatol 1996; 14: S31-S5.
126. Magro CM, Crowson AN, Peeling, R. Vasculitis as the basis of cutaneous lesions in Reiter's disease. Hum Pathol 1995; 26: 633-8.
127. Blanchin S, Estienne V, Durand-Gorde JM, Carayon P, Ruf J. Complement activation by direct C4 binding to thyroperoxidase in Hashimoto's thyroiditis. Endocrinology 2003; 144: 5422-9.
128. Okosieme OE, Parkes AB, McCullough B, et al. Complement activation in postpartum thyroiditis. QJM 2002; 95: 173-9.
129. Parkes AB, Othman S, Hall R, John R, Lazarus JH. The role of complement in the pathogenesis of postpartum thyroiditis. J Clin Endocrinol Metab 1994; 79: 395-400.
130. Ebert EC, Geng X, Lin J, Das KM. Autoantibodies against human tropomyosin isoform 5 in ulcerative colitis destroys colonic epithelial cells through antibody and complement-mediated lysis. Cell Immunol 2006; 244: 43-9.
131. Zimmermann-Nielsen E, Grønbaek H, Dahlerup JF, Baatrup G, Thorlacius-Ussing O. Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis. BMC Gastroenterol 2005; 5: 31.
132. Coremans IE, Daha MR, van der Voort EA, Muizert Y, Halma C, Breedveld FC. Antibodies against C1q in anti-glomerular basement membrane nephritis. Clin Exp Immunol 1992; 87: 256-60.
133. Engström G, Hedblad B, Eriksson KF, Janzon L, Lindgärde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 2005; 54: 570-5.
134. Hoffman WH, Cudrici CD, Zafranskaia E, Rus H. Complement activation in diabetic ketoacidosis brains. Exp Mol Pathol 2006; 80: 283-8.
135. Jerath RS, Burek CL, Hoffman WH, Passmore GG. Complement activation in diabetic ketoacidosis and its treatment. Clin Immunol 2005; 116: 11-7.
136. Hansen TK. Mannose-binding lectin (MBL) and vascular complications in diabetes. Horm Metab Res 2005; 37: 95-8.
137. Bouwman LH, Eerligh P, Terpstra OT, et al. Elevated levels of mannose-binding lectin at clinical manifestation of type 1 diabetes in juveniles. Diabetes 2005; 54: 3002-6.
138. Hovind P, Hansen TK, Tarnow L, et al. Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. Diabetes 2005; 54: 1523-7.
139. Saraheimo M, Forsblom C, Hansen TK, et al. Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia 2005; 48: 198-202.
140. Tandon N, Yan SL, Morgan BP, Weetman AP. Expression and function of multiple regulators of complement activation in autoimmune thyroid disease. Immunology 1994; 81: 643-7.
141. Gendek-Kubiak H, Gendek EG. Immunolocalization of protectin (CD59) and macrophages in polymyositis and dermatomyositis. J Neuroimmunol 2004; 149: 187-94.
142. Gonçalves FG, Chimelli L, Sallum AM, Marie SK, Kiss MH, Ferriani VP. Immunohistological analysis of CD59 and membrane attack complex of complement in muscle in juvenile dermatomyositis. J Rheumatol 2002; 29: 1301-7.
143. Cuida M, Legler DW, Eidsheim M, Jonsson R. Complement regulatory proteins in the salivary glands and saliva of Sjögren's syndrome patients and healthy subjects. Clin Exp Rheumatol 1997; 15: 615-23.
144. Yoshida T, Kubota Y, Nishimoto M, Okada H, Hirashima M. CD35 expression on peripheral blood granulocytes of patients with atopic dermatitis. J Dermatol Sci 2002; 28: 42-7.
145. Isolauri E, Pelto L, Nuutila J, Majamaa H, Lilius EM, Salminen S. Altered expression of IgG and complement receptors indicates a significant role of phagocytes in atopic dermatitis. J Allergy Clin Immunol 1997; 99: 707-13.
146. Sadallah S, Lach E, Lutz HU, Schwarz S, Guerne PA, Schifferli JA. CR1, CD35 in synovial fluid from patients with inflammatory joint diseases. Arthritis Rheum 1997; 40: 520-6.
147. Birmingham DJ, Gavit KF, McCarty SM, et al. Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare. Clin Exp Immunol 2006; 143: 274-80.
148. Scheinin T BT, Halme L, Kontiainen S, Bjørge L, Meri S. Decreased expression of protectin (CD59) in gut epithelium in ulcerative colitis and Crohn's disease. Hum Pathol 1999; 30: 1427-30.
149. Kohno H, Mizuno M, Nasu J, et al. Stool decay-accelerating factor as a marker for monitoring the disease activity during leukocyte apheresis therapy in patients with refractory ulcerative colitis. J Gastroenterol Hepatol 2005; 20: 73-8.
150. Illges H, Braun M, Peter HH, Melchers I. Reduced expression of the complement receptor type 2 (CR2, CD21) by synovial fluid B and T lymphocytes. Clin Exp Immunol 2000; 122: 270-6.
151. Astier AL. T-cell regulation by CD46 and its relevance in multiple sclerosis. Immunology 2008; 124: 149-54.
152. Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP. Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis. Clin Exp Immunol 1997; 110: 45-52.
153. Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP. Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis. Clin Exp Immunol 2000; 119: 210-6.
154. Mizuno M, Nishikawa K, Spiller OB, et al. Membrane complement regulators protect against the development of type II collageninduced arthritis in rats. Arthritis Rheum 2001; 44: 2425-34.
155. Williams AS, Mizuno M, Richards PJ, Holt DS, Morgan BP. Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis Rheum 2004; 50: 3035-44.
156. Nguyen C, Cornelius J, Singson E, Killedar S, Cha S, Peck AB. Role of complement and B lymphocytes in Sjögren's syndrome-like autoimmune exocrinopathy of NOD.B10-H2b mice. Mol Immunol 2006; 43: 1332-9.
157. Inoue K, Niesen N, Biesecker G, Milgrom F, Albini B. Role of late complement components in experimental autoimmune thyroiditis. Clin Immunol Immunopathol 1993; 66: 1-10.
158. Morgan BP, Chamberlain-Banoub J, Neal JW, Song W, Mizuno M, Harris CL. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol 2006; 146: 294-302.
159. Assmann KJ, Ronco P, Tangelder MM, Lange WP, Verroust P, Koene RA. Comparison of antigenic targets involved in antibodymediated membranous glomerulonephritis in the mouse and rat. Am J Pathol 1985; 121: 112-22.
160. Shike T, Isome M, Mizuno M, et al. Implication of the complement system in the induction of anti-glomerular basement membrane glomerulonephritis in WKY rats. Pathol Int 2003; 53: 757-61.
161. van den Berg CW, Aerts PC, van Dijk H. In vivo anticomplementary activities of the cobra venom factors from Naja naja and Naja haje. J Immunol Methods 1991; 136: 287-94.
162. Fritzinger DC, Hew BE, Lee JQ, et al. Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents. Adv Exp Med Biol 2008; 632: 293-307.
163. Metcalfe RA, McIntosh RS, Morgan BP, Levin JL, Weetman AP. The effect of soluble complement receptor 1 (sCR1) and human thyroid antibodies on the course of experimental autoimmune thyroiditis in rats. Autoimmunity 1996; 23: 1-8.
164. Quigg RJ, Kozono Y, Berthiaume D, et al. Blockade of antibodyinduced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol 1998; 160: 4553-60.
165. Wada J, Shintani N, Kikutani K, Nakae T, Yamauchi T, Takechi K. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin Exp Immunol 2001; 124: 282-9.
166. Tran GT, Hodgkinson SJ, Carter N, Killingsworth M, Spicer ST, Hall BM. Attenuation of experimental allergic encephalomyelitis in complement component 6-deficient rats is associated with reduced complement C9 deposition, P-selectin expression, and cellular infiltrate in spinal cords. J Immunol 2002; 168: 4293-300.
167. Chamberlain-Banoub J, Neal JW, Mizuno M, Harris CL, Morgan BP. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol 2006; 146: 278-86.
168. Reiman R, Gerard C, Campbell IL, Barnum SR. Disruption of the C5a receptor gene fails to protect against experimental allergic encephalomyelitis. Eur J Immunol 2002; 32: 1157-63.
169. Smith SS, Ludwig M, Wohler JE, Bullard DC, Szalai A, Barnum SR. Depletion of both ICAM-1 and C3 engances severity of experimental autoimmune encephalomyelitis compared to C3deficient mice. Neurosci Lett 2008; 442: 158-60.
170. Østergaard J, Thiel S, Gadjeva M, Hansen TK, Rasch R, Flyvbjerg A. Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice. Diabetologia 2007; 50: 1541-9.
171. Kuhn KA, Cozine CL, Tomooka B, Robinson WH, Holers VM. Complement receptor CR2/CR1 deficiency protects mice from collagen-induced arthritis and associates with reduced autoantibodies to type II collagen and citrullinated antigens. Mol Immunol 2008; 45: 2808-19.
172. Boackle SA, Holers VM. Role of complement in the development of autoimmunity. Curr Dir Autoimmun 2003; 6: 154-68.
173. Kaminski HJ, Kusner LL, Richmonds C, Medof ME, Lin F. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Exp Neurol 2006; 202: 287-93.
174. Sogabe H, Nangaku M, Ishibashi Y, et al. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J Immunol 2001; 167: 2791-7.
175. Miwa T, Maldonado MA, Zhou L, et al. Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms. Am J Pathol 2007; 170: 1258-66.
176. Sturfelt G, Rydgren L, Truedsson L, Alm P, Sjoholm AG. C1 inhibitor deficiency in a patient with rheumatoid arthritis-increased risk of adverse effects of penicillamine? J Rheumatol 1996; 23: 378-81.
177. Wisnieski JJ, Naff GB. Serum IgG antibodies to C1q in hypocomplementemic urticarial vasculitis syndrome. Arthritis Rheum 1989; 32: 1119-27.
178. Ghebrehiwet B, Peerschke EI. Role of C1q and C1q receptors in the pathogenesis of systemic lupus erythematosus. Curr Dir Autoimmun 2004; 7: 87-97.
179. Hoppenreijs EP, van Dijken PJ, Kabel PJ, Draaisma JM. Hereditary C1q deficiency and secondary Sjögren's syndrome. Ann Rheum Dis 2004; 63: 1524-5.
180. Leddy JP, Griggs RC, Klemperer MR, Frank MM. Hereditary complement (C2) deficiency with dermatomyositis. Am J Med 1975; 58: 83-91.
181. D'Cruz D, Taylor J, Ahmed T, Asherson R, Khamashta M, Hughes GR. Complement factor 2 deficiency: a clinical and serological family study. Ann Rheum Dis 1992; 51: 1254-6.
182. Efthimiou J, D'Cruz D, Kaplan P, Isenberg D. Heterozygous C2 deficiency associated with angioedema, myasthenia gravis, and systemic lupus erythematosus. Ann Rheum Dis 1986; 45: 428-30.
183. McLean RH, Weinstein A, Chapitis J, Lowenstein M, Rothfield NF. Familial partial deficiency of the third component of complement (C3) and the hypocomplementemic cutaneous vasculitis syndrome. Am J Med 1980; 68: 549-58.
184. Lhotta K, Kronenberg F, Joannidis M, Feichtinger H König P. Wegener's granulomatosis and Henoch-Schönlein purpura in a family with hereditary C4 deficiency. Adv Exp Med Biol 1993; 336: 415-8.
185. Schoonbrood TH, Hannema A, Fijen CA, Markusse HM, Swaak AJ. C5 deficiency in a patient with primary Sjögren's syndrome. J Rheumatol 1995; 22: 1389-90.
186. Wisnieski JJ, Naff GB, Pensky J, Sorin SB. Terminal complement component deficiencies and rheumatic disease: development of a rheumatic syndrome and anticomplementary activity in a patient with complete C6 deficiency. Ann Rheum Dis 1985; 44: 716-22.
187. Reinitz E, Lawrence M, Diamond B, Keiser H, Alper C. Arthritis and antinuclear antibodies (ANA) with inherited deficiency of the sixth component of complement (C6). Ann Rheum Dis 1986; 45: 431-44.
188. Trapp RG, Mooney E, Coleman TH, Forristal J, Herman JH. Hereditary complement (C6) deficiency associated with systemic lupus erythematosus, Sjögren's syndrome and hyperthyroidism. J Rheumatol 1987; 14: 1030-3.
189. Dragon-Durey MA, Fremeaux-Bacchi V, Blouin J, Barraud D, Fridman WH, Kazatchkine MD. Restricted genetic defects underlie human complement C6 deficiency. Clin Exp Immunol 2003; 132: 87-91.
190. Wulffraat NM, Sanders EA, Fijen CA, Hannema A, Kuis W, Zegers BJ. Deficiency of the beta subunit of the eighth component of complement presenting as arthritis and exanthem. Arthritis Rheum 1994; 37: 1704-6.
191. Ichikawa E, Furuta J, Kawachi Y, Imakado S, Otsuka F. Hereditary complement (C9) deficiency associated with dermatomyositis. Br J Dermatol 2001; 144: 1080-3.
192. Lee SL, Wallace SL, Barone R, Blum L, Chase PH. Familial deficiency of two subunits of the first component of complement. C1r and C1s associated with a lupus erythematosus-like disease. Arthritis Rheum 1978; 21: 958-67.
193. Irestedt M, Svensson A, Mansson T. Subtotal C4 deficiency and SLE-like disease. Acta Derm Venereol 1986; 66: 67-70.
194. Alcalay M, Bontoux D, Peltier A, Vial MC, Vilde JM, Wautier JL. C7 deficiency, abnormal platelet aggregation, and rheumatoid arthritis. Arthritis Rheum 1981; 24: 102-3.
195. Amadei N, Baracho GV, Nudelman V, Bastos W, Florido MP, Isaac L. Inherited complete factor I deficiency associated with systemic lupus erythematosus, higher susceptibility to infection and low levels of factor H. Scand J Rheumatol 2001; 53: 615-21.
196. Kilpatrick DC. Mannan-binding lectin: clinical significance and applications. Biochim Biophys Acta 2002; 1572: 401-13.
197. Gupta B, Agrawal C, Raghav SK, et al. Association of mannose-binding lectin gene (MBL2) polymorphisms with rheumatoid arthritis in an Indian cohort of case-control samples. J Hum Genet 2005; 50: 583-91.
198. Chen X, Katoh Y, Nakamura K, et al. Single nucleotide polymorphisms of Ficolin 2 gene in Behçet's disease. J Dermatol Sci 2006; 43: 201-5.
199. Trapp RG, Fletcher M, Forristal J, West CD. C4 binding protein deficiency in a patient with atypical Behçet's disease. J Rheumatol 1987; 14: 135-8.
200. Ekdahl KN, Nilsson B. Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets. J Immunol 1999; 162: 7426-33.
201. Vivanco F, Muñoz E, Vidarte L, Pastor C. The covalent interaction of C3 with IgG immune complexes. Mol Immunol 1999; 36: 843-52.
202. Einav S, Pozdnyakova OO, Ma M, Carroll MC. Complement C4 is protective for lupus disease independent of C3. J Immunol 2002; 168: 1036-41.
203. Nusinow SR, Zuraw BL, Curd JG. The hereditary and acquired deficiencies of complement. Med Clin North Am 1985; 69: 487-504.
204. Edberg JC, Tosic L, Wright EL, Sutherland WM, Taylor RP. Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes. J Immunol 1988; 141: 4258-65.
205. Arora M AR, Tiwari SC, Das N, Srivastava LM. Expression of complement regulatory proteins in diffuse proliferative glomerulonephritis. Lupus 2000; 9: 127-31.
206. Buyon JP, Shadick N, Berkman R, et al. Surface expression of Gp 165/95, the complement receptor CR3, as a marker of disease activity in systemic Lupus erythematosus. Clin Immunol Immunopathol 1988; 46: 141-9.
207. Clancy RM. Circulating endothelial cells and vascular injury in systemic lupus erythematosus. Curr Rheumatol Rep 2000; 2: 39-43.
208. Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J. Circulating activated endothelial cells in systemic lupus erythematosus: further evidence for diffuse vasculopathy. Arthritis Rheum 2001; 44: 1203-8.
209. Bao L, Osawe I, Haas M, Quigg RJ. Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol 2005; 175: 1947-55.
210. Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol 2005; 35: 2496-506.
211. Bao L, Quigg RJ. Complement in lupus nephritis: the good, the bad, and the unknown. Semin Nephrol 2007; 27: 69-80.
212. Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003; 108: 1176-83.
213. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 internatinal consensus alogrithm for the diagnosis, therapy, and management of hereditary angioedema. J Allergy Clin Immunol 2004; 114: 629-937.
214. Luzzatto L, Gianfaldoni G. Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria. Int J Hematol 2006; 84: 104-12.
215. Chiu TL, Mulakala C, Lambris JD, Kaznessis YN. Development of a new pharmacophore model that discriminates active compstatin analogs. Chem Biol Drug Des 2008; 72: 249-56.
216. Ricklin D, Lambris JD. Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 2008; 632: 273-92.
217. Nunn MA, Sharma A, Paesen GC, et al. Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J Immunol 2005; 174: 2084-91.
218. Soltys J, Kusner LL, Young A, et al. Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 2009; 65: 67-75.
219. Hepburn NJ, Williams AS, Nunn MA, et al. In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata. J Biol Chem 2007; 282: 8292-9.
220. Rooijakkers SH, Milder FJ, Bardoel BW, Ruyken M, van Strijp JA, Gros P. Staphylococcal complement inhibitor: structure and active sites. J Immunol 2007; 179: 2989-98.
221. Rooijakkers SH, Ruyken M, Roos A, et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat Immunol 2005; 6: 920-7.
222. Eriksson H, Sjögren HO. Inhibition of activation of human T lymphocytes by the complement C1 esterase inhibitor. Immunology 1995; 86: 304-10.
223. Kirschfink M, Nurnberger W. C1 inhibitor in anti-inflammatory therapy: from anial experiment to clinical application. Mol Immunol 1999; 36: 225-32.
224. Nissen MH, Bregenholt S, Nording JA, Claesson MH. C1-esterase inhibitor blocks T lymphocyte proliferation and cytotoxic T lymphocyte generation in vitro. Int Immunol 1998; 10: 167-73.
225. Alexander JJ, Jacob A, Vezina P, Sekine H, Gilkeson GS, Quigg RJ. Absence of functional alternative complement pathway alleviates lupus cerebritis. Eur J Immunol 2007; 37: 1691-701.
226. Bao L, Haas M, Boackle SA, et al. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol 2002; 168: 3601-7.
227. Hepburn NJ, Chamberlain-Banoub JL, Williams AS, Morgan BP, Harris CL. Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo. Mol Immunol 2007; 45: 395-405.
228. Bao L, Zhou J, Holers VM, Quigg RJ. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation. J Am Soc Nephrol 2003; 14: 2516-25.
229. Bao L, Haas M, Kraus DM, et al. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol 2003; 14: 670-9.
230. Song H, He C, Knaak C, Guthridge JM, Holers VM, Tomlinson S. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest 2003; 111: 1875-85.
231. Atkinson C, Qiao F, Song H, Gilkeson GS, Tomlinson S. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol 2008; 180: 1231-88.
232. Song H, Qiao F, Atkinson C, Holers VM, Tomlinson S. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol 2007; 179: 7860-70.
233. Boackle SA, Culhane KK, Brown JM, et al. CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in the RL/lpr model of SLE. Autoimmunity 2004; 37: 111-23.
234. Birrell L, Kulik L, Morgan BP, Holers VM, Marchbank K. B cells from mice prematurely expressing human complement receptor type 2 are unresponsive to T-dependent antigens. J Immunol 2005; 174: 6974-82.
235. Romay-Penabad Z, Liu XX, Montiel-Manzano G, Papalardo De Martínez E, Pierangeli SS. C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. Ann N Y Acad Sci 2007; 1108: 554-66.
236. Morgan BP, Harris CL. Complement therapeutics; history and current progress. Mol Immunol 2003; 40: 159-70.
237. Zhang B, Jiang Y, Yang Y, Peng F, Hu X. Correlation between serum thyroxine and complements in patients with multiple sclerosis and neuromyelitis optica. Neuro Endocrinol Lett 2008; 29: 256-60.
238. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007; 69: 2221-31.
239. Yuki N. Infectious origins of, and molecular mimicry in, GuillainBarré and Fisher syndromes. Lancet Infect Dis 2001; 1: 29-37.
240. Vedeler CA, Gilhus NE, Matre R. Expression of complement C3b/C4b receptors (CR1) on erythrocytes from patients with myasthenia gravis. Acta Neurol Scand 1990; 82: 259-62.
241. Barohn RJ, Brey RL. Soluble terminal complement components in human myasthenia gravis. Clin Neurol Neurosurg 1993; 95: 285-90.
242. Kahan A, Collantes-Estevez E, Barel M, Frade R, Amor B. Expression of complement receptors (CR1 and CR3) and Fc gamma RIII on polymorphonuclears from patients with spondylarthropathies. Clin Exp Rheumatol 1993; 11: 27-34.
243. Teisberg P, Fauchald P, Flatmark A, et al. Serial complement studies in a patient with Goodpasture's syndrome treated with bilateral nephrectomy and renal transplantation. Am J Med 1975; 59: 563-7.
244. Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 444-8.
245. Cicardi M, Bisiani G, Gugno M, Spath P, Agostoni A. Autoimmune C1 inhibitor deficiency: report of eight patients. Am J Med 1993; 95: 169-175.
246. Cicardi M, Beretta A, Colombo M, Gioffre D, Cugno M, Agostoni A. Relevance of lymphoproliferative disorders and anti-C1 inhibitior autoantibodies in aquired angio-oedema. Clin Exp Immunol 1996; 106: 475-480.
247. Ponce IM, Caballero T, Reche M, Piteiro AB, Lopez-Serrano MC, Fontan G, Lopez-Trascasa M. Polyclonal autoantibodies against C1 inhibitor in a case of aquired angioedema. Ann Allergy Asthma Immunol 2002; 88: 632-637.
248. Czech W, Dichmann S, Herouy Y, et al. Distinct amplification of the C5a-receptor pathways in normodense and hypodense eosinophils of patients with atopic dermatitis. Scand J Immunol 2001; 53: 235-9.
249. Breathnach R, Donahy C, Jones BR, Bloomfield FJ. Increased leukotriene B(4) production, complement C3 conversion and acid hydrolase enzyme concentrations in different leucocyte subpopulations of dogs with atopic dermatitis. Vet J 2006; 171: 106-13.
250. de Messias IT, von Kuster LC, Santamaria J, Kajdacsy-Balla A. Complement and antibody deposition in Brazilian pemphigus foliaceus and correlation of disease activity with circulating antibodies. Arch Dermatol 1988; 124: 1664-8.
251. Betterle C, Mazzi PA, Pedini B, Accordi F, Cecchetto A, Presotto F. Complement-fixing gastric parietal cell autoantibodies. A good marker for the identification of type A chronic atrophic gastritis. Autoimmunity 1988; 1: 267-74.
252. Okazaki K, Uchida K, Fukui T. Recent advances in autoimmune pancreatitis: concept, diagnosis, and pathogens. J Gastroenterol 2008; 43: 409-18.
253. Garred P, Lyon H, Christoffersen P, Mollnes TE, Tranum-Jensen J. Deposition of C3, the terminal complex and vitronectin in in primary biliary cirrhosis and primary sclerosing cholangitis. Liver 1993; 13: 305-10.
254. Brons RH, de Jong MC, de Boer NK, Stegeman CA, Kallenberg CG, Tervaert JW. Detection of immune deposits in skin lesions of patients with Wegener's granulomatosis. Ann Rheum Dis 2001; 60: 1097-102.
255. Inoue A, Koh CS, Tsukada N, Yanagisawa N. Allergic granulomatous angiitis and peripheral nerve lesion. Intern Med 1992; 31: 989-93.
256. Smith GC, Davidson JE, Hughes DA, Holme E, Beattie TJ. Complement activation in Henoch-Schönlein purpura. Pediatr Nephrol 1997; 11: 477-80.
257. Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M. Complement activation through the lectin pathway in patients with HenochSchönlein purpura nephritis. Am J Kidney Dis 2000; 35: 401-7.
258. Shin JI, Park JM, Shin YH, Lee JS, Jeong HJ, Kim HS. Serum IgA/C3 ratio may be a useful marker of disease activity in severe Henoch-Schönlein nephritis. Nephron Clin Pract 2005; 101: 72-8.
259. Barnes L, Rodnan GP, Medsger TA, Short D. Eosinophilic fasciitis. A pathologic study of twenty cases. Am J Pathol 1979; 96: 493-517.
260. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995; 92: 8955-9.
261. Linton SM, Williams AS, Dodd I, Smith R, Williams BD, Morgan BP. Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat. Arthritis Rheum 2000; 43: 2590-7.
262. Kourounakis L, Nelson RAJ, Kupusta MA. The effect of a cobra venom factor on complement and adjuvant-induced disease in rats. Arthritis Rheum 1973; 16: 71-6.
263. Santos LL, Morand EF, Hutchinson P, Boyce NW, Holdsworth SR. Anti-neutrophil monoclonal antibody therapy inhibits the development of adjuvant arthritis. Clin Exp Immunol 1997; 107: 248-53.
264. Savige JA, Dash AC, Rees AJ. Exaggerated glomerular albuminuria after cobra venom factor in anti-glomerular basement membrane disease. Nephron 1989; 52: 29-35.
265. Kondo C, Mizuno M, Nishikawa K, Yuzawa Y, Hotta N, Matsuo S. The role of C5a in the development of thrombotic glomerulonephritis in rats. Clin Exp Immunol 2001; 124: 323-9.
266. Nishikage H, Baranyi L, Okada H, et al. The role of a complement regulatory protein in rat mesangial glomerulonephritis. J Am Soc Nephrol 1995; 6: 234-41.
267. Bagchus WM, Hoedemaeker PJ, Rozing J, Bakker WW. Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat. Lab Invest 1986; 55: 680-7.
268. Couser WG, Johnson RJ, Young BA, Yeh CG, Toth CA, Rudolph AR. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 1995; 5: 1888-94.
269. Nangaku M, Alpers CE, Pippin J, et al. CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats. J Am Soc Nephrol 1998; 9: 590-7.
270. Linington C, Morgan BP, Scholding J, Wilkins P, Piddlesden S, Compston DA. The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain 1989; 112: 895-911.
271. Mead RJ, Singhrao SK, Neal JW, Lassmann H, Morgan BP. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol 2002; 168: 458-65.
272. Stahel PF, Frei K, Fontana A, Eugster HP, Ault BH, Barnum SR. Evidence for intrathecal synthesis of alternative pathway complement activation proteins in experimental meningitis. Am J Pathol 1997; 151: 897-904.
273. Kadurugamuwa JL, Hengstler B, Bray MA, Zak O. Inhibition of complement-factor-5a-induced inflammatory reactions by prostaglandin E2 in experimental meningitis. J Infect Dis 1989; 160: 715-9.
274. Jha P, Sohn JH, Xu Q, et al. The complement system plays a critical role in the development of experimental autoimmune anterior uveitis. Invest Ophthalmol Vis Sci 2006; 47: 1030-8.
275. Weetman AP, Cohen SB, Oleesky DA, Morgan BP. Terminal complement complexes and C1/C1 inhibitor complexes in autoimmune thyroid disease. Clin Exp Immunol 1989; 77: 25-30.
276. Piddlesden SJ, Jiang S, Levin JL, Vincent A, Morgan BP. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 1996; 71: 173-7.
277. Tüzün E, Saini SS, Morgan BP, Christadoss P. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis. J Neuroimmunol 2006; 181: 29-33.
278. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like antoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996; 93: 8563-8.
279. Karp CL, Grupe A, Schadt E, et al. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol 2000; 1: 221-6.
280. Drouin SM, Kildsgaard J, Haviland J, et al. Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol 2001; 166: 2025-32.
281. Amano MT, Ferriani VP, Florido MP, et al. Genetic analysis of complement C1s deficiency associated with systemic lupus erythematosus highlights alternative splicing of normal C1s gene. Mol Immunol 2008; 45: 1693-702.
282. Steinsson K, McLean RH, Merrow M, Rothfield NF, Weinstein A. Selective complete Clq deficiency associated with systemic lupus erythematosus. J Rheumatol 1983; 10: 590-4.
283. Roberts JL, Schwartz MM, Lewis EJ. Hereditary C2 deficiency and systemic lupus erythematosus associated with severe glomerulonephritis. Clin Exp Immunol 1978; 31: 328-38.
284. Tsukamoto H, Horiuchi T, Kokuba H, et al. Molecular analysis of a novel hereditary C3 deficiency with systemic lupus erythematosus. Biochem Biophys Res Commun 2005; 330: 298-304.
285. Ripoche J, Fontaine M, Godin M, Hauptmann G, Goetz J. Partial deficiency of the fourth component of human complement (C4) and autoantibody directed against C4 in a patient with SLE. Ann Immunol (Paris) 1983; 134: 233-45.
286. Segurado OG, Arnaiz-Villena AA, Iglesias-Casarrubios P, et al. Combined total deficiency of C7 and C4B with systemic lupus erythematosus (SLE). Clin Exp Immunol 1992; 87: 410-4.
287. Jasin HE. Absence of the eighth component of complement in association with systemic lupus erythematosus-like disease. J Clin Invest 1977; 60: 709-15.
288. Pickering RJ, Rynes RI, LoCascio N, Monahan JB, Sodetz JM. Identification of the alpha-gamma subunit of the eighth component of complement (C8) in a patient with systemic lupus erythematosus and absent C8 activity: patients and family studies. Clin Immunol Immunopathol 1982; 23: 323-34.
289. Takeda I, Igarashi S, Nishimaki T, Kasukawa R. A case of systemic lupus erythematosus in late component (C9) complement deficiency. Ryumachi. 1994;34(3):628-32.
290. Sugimoto M, Nishikai M, Sato A, et al. SLE-like and sicca symptoms in late component (C9) complement deficiency. Ann Rheum Dis 1987; 46: 153-5.
291. Koide M, Shirahama S, Tokura Y, Takigawa M, Hayakawa M, Furukawa F. Lupus erythematosus associated with C1 inhibitor deficiency. J Dermatol 2002; 29: 503-7.